Shares of medical device company DexCom (NASDAQ:DXCM) jumped 2.6% in the morning session after the company announced it would ...

DexCom announced that Chairman and CEO Kevin R. Sayer has taken a temporary medical leave as of September 14, 2025, with President and COO Jacob S. Leach appointed interim CEO and Mark Foletta as ...

The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...

At Dexcom (Nasdaq:DXCM), one of the leaders in continuous glucose monitoring (CGM), innovation continues to roll on.

Citi analyst Joanne Wuensch maintained a Buy rating on Dexcom today. The company’s shares closed yesterday at $76.55. Elevate Your Investing Strategy: Take advantage of TipRanks ...

The company is presenting several abstracts during the five-day conference showcasing clinical and real-world evidence that ...

In a report released on September 14, Joanne Wuensch from Citi reiterated a Buy rating on Dexcom. The company’s shares closed yesterday at $76.55. Elevate Your Investing Strateg ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company. It focuses on the design, development, and ...

Two major diabetes tech companies, Dexcom and Insulet, are making changes to their C-suites.  | The changes at the diabetes tech companies include Dexcom announcing that outgoing CEO Kevin Sayer is ...

DexCom, Inc. ( NASDAQ: DXCM) Baird Global Healthcare Conference 2025 September 10, 2025 2:00 PM EDT Next presentation this afternoon is from DexCom, a leader in developing and commercializing ...

Shares of DexCom Inc. advanced 6.22% to $78.92 Wednesday, on what proved to be an all-around mixed trading session for the ...

New data suggest antithymocyte globulin, verapamil, and baricitinib might help preserve beta cell function in new-onset type ...